Latest Industry Insights

In this interview with Bryan Kobel, CEO of TC Biopharm, we find out about gamma-delta T-cell therapy, including how it works, its applications and how TC Biopharm developed its pioneering gamma-delta treatment for acute myeloid leukemia.

Technology Networks spoke to Dr. Cenk Sumen, chief scientific officer of MaxCyte, about their pioneering cell engineering platform.

Developing and manufacturing biotherapeutics at scale requires thorough analysis of the active substance’s characteristics to ensure it fulfils both efficacy and safety requirements. Analytical technologies, such as mass spectrometry, are key tools adopted in this process.

To learn more about new technologies being developed for drug discovery and cell therapy, Technology Networks spoke to bit.bio's Dr. Farah Patell-Socha and Furqan Iqbal.

In this interview, Gregory J. McKenzie, PhD, discusses the impact of antibiotics, the introduction of new bacteria into the microbiome and the potential of human breast milk-based therapeutics.

The science and medicine worlds are experiencing a new revolution, and this time the protagonist is the mRNA molecule. In this article, we explore why bioplatforms support this revolution.

Technology Networks learns about the "unusual" spread of the monkeypox virus in non-endemic countries, possible vaccination strategies against the virus and if there are effective treatments available.

Research is advancing exciting areas of science at an unprecedented pace, but the disposable materials, powered equipment and shipping associated with experiments, sample storage and transport of reagents contribute to high energy consumption and significant waste. How are researchers bringing sustainability to scientific discovery?

In April 2022, Cancer Research UK unveiled Cancer Research Horizons, its new approach to driving innovation in the field. Technology Networks had the opportunity to speak with two members of Cancer Research Horizon’s executive leadership team to learn more about some of the cutting-edge experimental capabilities that will be used to interrogate cancer biology more thoroughly.

We spoke to Geoff Winkett and Michel van den Berge from Agilent, about the concerns they hear from their customers in the pharmaceutical and biopharmaceutical sector and how they are helping to address them.